Introduction to Oxford Biomedica

Oxford Biomedica plc (Oxford Biomedica) is a pioneering gene and cell therapy company headquartered in Oxford, United Kingdom. Founded in 1995, the company has established itself as a global leader in the development and manufacture of viral vectors, particularly lentiviral vectors, which are essential for gene therapies. With a strong focus on quality, innovation, and scalability, Oxford Biomedica serves as a strategic partner to top pharmaceutical and biotechnology firms worldwide. The company’s mission is to transform the lives of patients with serious diseases by delivering advanced therapies, and its reputation is built on decades of scientific excellence and manufacturing expertise. As a Healthcare sector leader, Oxford Biomedica is recognized for its robust platform technologies, including the LentiVector® platform, which has been validated in multiple clinical and commercial applications. The company’s commitment to regulatory compliance and state-of-the-art facilities, such as its Windrush Court and Oxford Science Park sites, underscores its position as a trusted partner in the gene therapy ecosystem. Organizations such as Novartis, Bristol-Myers Squibb, and other major biopharma companies rely on Oxford Biomedica’s services to accelerate their gene therapy pipelines. With over 900 employees and a growing footprint, Oxford Biomedica continues to shape the future of medicine, making it an exceptional workplace for professionals passionate about healthcare innovation.

Company History and Business Evolution

Oxford Biomedica was founded in 1995 as a spin-out from Oxford University, initially focusing on gene therapy research. The early years were dedicated to developing its proprietary LentiVector® platform, which became a cornerstone for delivering therapeutic genes. In 2001, the company went public on the London Stock Exchange (LSE: OXB), raising capital to expand its R&D capabilities. A major milestone occurred in 2014 when Oxford Biomedica partnered with Novartis to manufacture Kymriah, the first CAR-T therapy approved in the US and Europe, using its lentiviral vector technology. This collaboration catapulted the company into the global spotlight and validated its manufacturing prowess. Throughout the 2010s, Oxford Biomedica expanded its facilities, including the opening of the Windrush Court manufacturing site in 2017 and the acquisition of the cell and gene therapy manufacturing business from Cobra Biologics in 2021. This acquisition strengthened its plasmid DNA and viral vector manufacturing capabilities. The company also launched its oncology division in 2019, developing novel immunotherapies. In 2023, Oxford Biomedica announced a strategic partnership with a major pharmaceutical company to develop next-generation gene therapies, further cementing its industry leadership. The company’s evolution from a university spin-out to a commercial powerhouse reflects its ability to innovate and adapt to the rapidly changing gene therapy landscape. Today, Oxford Biomedica operates multiple GMP manufacturing facilities and has a robust pipeline of over 15 partnered programs in clinical development.

Oxford Biomedica at a Glance

• Headquarters: Oxford, United Kingdom
• Founded: 1995
• CEO: Dr. John Dawson (as of 2024)
• Industry: Biotechnology / Gene and Cell Therapy
• Stock Symbol: LSE: OXB
• Revenue: Approximately £105 million (FY 2023)
• Employees: Over 900 (2024)
• Key Product: LentiVector® platform
• Manufacturing Facilities: Windrush Court, Oxford Science Park
• Global Partners: Novartis, Bristol-Myers Squibb, among others
• Specialization: Lentiviral vector design, development, and GMP manufacturing
• Clinical Pipeline: Over 15 partnered programs
• Regulatory Approvals: Kymriah (CAR-T) relies on Oxford Biomedica’s vectors
• Awards: Multiple industry awards for innovation and manufacturing excellence
• Expansion: Acquisition of Cobra Biologics (2021)
• R&D Focus: Oncology, rare diseases, ocular and CNS disorders
• Quality Certifications: GMP, ISO 9001
• Social Responsibility: Active in community science education and sustainability initiatives
• Website: www.oxb.com
• LinkedIn Followers: Over 60,000 (2024)

Mission, Vision, and Core Corporate Values

Oxford Biomedica’s mission is to deliver life-changing gene therapies to patients by providing best-in-class viral vectors and innovative therapeutic solutions. The company envisions a world where genetic diseases are treated effectively through advanced therapies, reducing suffering and improving quality of life. Core values include scientific excellence, integrity, collaboration, and patient-centricity. The company fosters a culture of continuous learning and innovation, ensuring that employees are empowered to push boundaries. Oxford Biomedica is committed to ethical practices, transparency in clinical development, and maintaining the highest standards of quality and safety in manufacturing.

Business Strategy and Future Roadmap

Oxford Biomedica’s business strategy centers on three pillars: (1) expanding its CDMO (Contract Development and Manufacturing Organization) services to capture growing demand for viral vector production, (2) advancing its proprietary pipeline of gene therapies for oncology and rare diseases, and (3) investing in next-generation technologies such as alternative vector capsids and suspension cell culture processes. The company plans to increase manufacturing capacity by 50% by 2025 through facility expansions and process optimization. Strategic partnerships with big pharma remain a key growth driver, as evidenced by long-term supply agreements worth over £1 billion. Oxford Biomedica is also exploring new markets in Asia and North America, with potential joint ventures or licensing deals. The roadmap emphasizes sustainability, with goals to reduce carbon emissions by 30% by 2030. The company is also investing in digitalization, including AI-driven process analytics, to enhance yield and reduce costs.

Products, Technologies, and Services

Oxford Biomedica’s primary technology is the LentiVector® platform, a proprietary lentiviral vector system used for gene delivery. The platform enables stable, long-term expression of therapeutic genes and is used in both ex-vivo and in-vivo applications. The company offers a full spectrum of services from vector design and development to GMP manufacturing and regulatory support. Its CDMO services include cell line development, plasmid production, and fill-finish operations. Additionally, Oxford Biomedica develops its own pipeline of novel therapies, including candidate OXB-102 for Parkinson’s disease and OXB-203 for wet age-related macular degeneration. The company also provides process characterization and analytical method development, ensuring high-quality vector batches for clinical trials. With a focus on innovation, Oxford Biomedica is researching new capsid variants that improve targeting and reduce immunogenicity.

Industries and Markets Served

Oxford Biomedica primarily serves the pharmaceutical and biotechnology industries, focusing on companies developing gene and cell therapies. The company’s clients range from small biotechs to top-tier global pharma. Its vector manufacturing services are critical for clinical-stage and commercial programs in oncology, rare genetic diseases, central nervous system disorders, and ophthalmology. Oxford Biomedica also collaborates with academic institutions and non-profit organizations to advance gene therapy research. The company’s impact extends to regulatory agencies, as its validated platforms help streamline approval processes. Emerging markets include gene editing and RNA-based therapies, where Oxford Biomedica is exploring synergies with its vector technology.

Leadership and Management Philosophy

Oxford Biomedica’s leadership team is composed of seasoned scientists and business executives with deep expertise in gene therapy, manufacturing, and corporate strategy. CEO Dr. John Dawson, appointed in 2023, previously held senior roles at Roche and brings a focus on operational excellence and commercial growth. The management philosophy emphasizes data-driven decision-making, employee empowerment, and a collaborative culture. Regular town halls and transparent communication channels ensure alignment across the organization. The company invests in leadership development programs and mentorship, preparing the next generation of biotech leaders. Ethics and compliance are non-negotiable, with a robust code of conduct that guides all activities.

Corporate Events, Conferences, and Community Engagement

Oxford Biomedica actively participates in major industry conferences such as the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, the Cell & Gene Therapy World Congress, and the Bio International Convention. The company sponsors sessions on vector manufacturing innovations and presents research findings. Locally, Oxford Biomedica hosts open days at its facilities for students and educators, promoting STEM education. The company also runs a community grant program supporting health-related initiatives in Oxfordshire. Employee volunteer days are encouraged, with teams engaging in charity runs, blood drives, and environmental clean-ups.

Employees and Workplace Culture

Oxford Biomedica fosters an inclusive, innovative, and safety-oriented culture. Employees are encouraged to develop their skills through continuous training and career progression paths. The company offers competitive benefits, including pension schemes, health insurance, and share schemes. Flexible working arrangements are available where possible. The workplace is diverse, with employees from over 30 nationalities. Employee resource groups support various communities, such as women in science and LGBTQ+ networks. The company’s low turnover rate (around 8%) reflects high satisfaction. Regular team-building events and an annual company-wide celebration reinforce a sense of community.

Job Details & Requirements for this Posting

Role: Senior Scientist, Gene Therapy Process Development

Location: Oxford, UK
Job Type: Full-time
Salary: £65,000 - £85,000 per annum + benefits

Responsibilities

• Design and optimize lentiviral vector production processes from lab to pilot scale.
• Develop and execute upstream and downstream process development studies.
• Lead technology transfer activities to GMP manufacturing.
• Collaborate with analytical teams to characterize product quality attributes.
• Author technical reports, SOPs, and regulatory submissions.
• Mentor junior scientists and contribute to team goals.
• Ensure compliance with safety and quality standards.

Qualifications

• PhD in biochemical engineering, biotechnology, or related field; or MSc with 5+ years industry experience.
• Deep knowledge of viral vector production, particularly lentiviral vectors.
• Experience with cell culture, purification chromatography, and TFF.
• Familiarity with DOE and data analysis tools (e.g., JMP, Design-Expert).
• Excellent communication and problem-solving skills.
• Previous experience in GMP environment is a plus.

Why Join Oxford Biomedica

Join a world-class team at a company that is transforming gene therapy. You will work with cutting-edge technologies and have opportunities for career growth in a dynamic environment. Oxford Biomedica offers competitive compensation, a collaborative culture, and the chance to make a tangible impact on patients’ lives.

Customer Reviews and Industry Reputation

Oxford Biomedica is widely regarded as a reliable and innovative partner in the gene therapy space. Below is a comprehensive analysis of reviews and reputation across major platforms.

Glassdoor

On Glassdoor, Oxford Biomedica holds an overall rating of 4.1 out of 5 stars based on over 200 reviews. Employees praise the company’s meaningful work, advanced technology, and supportive management. Common positive themes include strong R&D culture, good benefits, and a friendly atmosphere. Constructive feedback mentions occasional silos between departments and pressure during project timelines. Senior leadership receives generally favorable reviews, with many noting transparency and approachability. The company’s commitment to employee development is highlighted, with opportunities for training and internal promotions.

Indeed

Indeed reviews show an average rating of 4.0 out of 5. Reviewers often highlight the exciting science and collaborative team environment. Many appreciate the fast-paced learning opportunities and the feeling of contributing to life-changing therapies. Areas for improvement include workload balancing and communication across shifts in manufacturing. Overall, 82% of reviewers would recommend Oxford Biomedica to a friend, and the majority approve of the CEO.

Gartner Peer Insights

While Oxford Biomedica is not a typical IT company, Gartner Peer Insights includes reviews from partners in the biopharma segment. Feedback emphasizes the company’s technical expertise and reliability as a CDMO. Specific mentions include high-quality vector batches and responsive project management. The company’s ability to adapt to changing requirements is a recurring positive point.

Trustpilot

Oxford Biomedica does not maintain a prominent Trustpilot page as it is primarily B2B. However, limited reviews exist from academic collaborators, with average scores around 4.5 emphasizing professionalism and scientific rigor. The lack of consumer-facing products means this platform has minimal presence.

G2

G2 reviews are sparse, but those available relate to Oxford Biomedica’s internal software tools for data management. Scores are around 4.2, citing ease of use and integration with lab systems. The company is seen as forward-thinking in adopting digital solutions.

Google Reviews

Google Reviews of Oxford Biomedica’s Oxford headquarters feature an average 4.3 rating. Comments focus on the modern facilities, pleasant campus, and professional staff. Some reviews from visitors note effective security and helpful reception. Employees occasionally post about positive experiences with the company canteen and work environment.

LinkedIn Reputation

LinkedIn is a strong platform for Oxford Biomedica, with over 60,000 followers. The company regularly posts about scientific achievements, job openings, and community engagement. Employee profiles often highlight pride in the company’s mission. The company’s LinkedIn page has a high engagement rate, with posts about partnerships and conference attendances receiving hundreds of reactions and shares. The overall sentiment is extremely positive, positioning Oxford Biomedica as an employer of choice in gene therapy.

Why Organizations Choose Oxford Biomedica

Organizations select Oxford Biomedica for its proven track record in viral vector manufacturing, regulatory expertise, and robust supply chain. The company’s LentiVector® platform has been used in approved products like Kymriah, reducing risk for partners. Oxford Biomedica offers end-to-end solutions, from early-stage development to commercial manufacturing, enabling faster time-to-market. Its dedicated project management teams ensure clear communication and on-time delivery. Furthermore, the company invests in capacity expansion, ensuring partners have access to the volume needed for global launches. The combination of scientific leadership, manufacturing reliability, and a patient-centric approach makes Oxford Biomedica the preferred partner for many leading biopharma companies.

Official Contact Information

For inquiries and assistance, please reach out to Oxford Biomedica using the following contact details:

Address: Windrush Court, Medawar Centre, Oxford Science Park, Oxford, OX4 4GA, United Kingdom
Contact Number: +44 (0)1865 783000
Support Number: +44 (0)1865 783001
Helpdesk Number: +44 (0)1865 783002
Website:www.oxb.com

Official Social Media Presence

• LinkedIn:Oxford Biomedica on LinkedIn
• Twitter/X:@oxfordbiomedica
• YouTube:Oxford Biomedica Channel
• Facebook:Oxford Biomedica Facebook

SEO FAQ Section

Oxford Biomedica is a gene and cell therapy company headquartered in Oxford, UK, specializing in the development and manufacture of viral vectors for advanced therapies.

Oxford Biomedica’s main offices and manufacturing facilities are located in Oxford Science Park, Oxford, United Kingdom.

The CEO of Oxford Biomedica is Dr. John Dawson, appointed in 2023, bringing extensive experience from Roche and other biotech firms.

Oxford Biomedica was founded in 1995 as a spin-out from Oxford University.

The LentiVector® platform is Oxford Biomedica’s proprietary lentiviral vector system used for gene delivery in therapeutic applications.

Oxford Biomedica offers CDMO services including vector design, process development, GMP manufacturing, and regulatory support for gene therapies.

Yes, Oxford Biomedica is listed on the London Stock Exchange under the ticker OXB.

Oxford Biomedica employs over 900 people as of 2024.

Oxford Biomedica focuses on oncology, rare diseases, CNS disorders, and ophthalmology.

Yes, Oxford Biomedica has partnerships with Novartis, Bristol-Myers Squibb, and other major pharmaceutical companies.

The salary range for a Senior Scientist at Oxford Biomedica is typically £65,000 to £85,000 per year, plus benefits.

Oxford Biomedica fosters an inclusive, innovative, and safety-focused culture with strong emphasis on professional development and collaboration.

You can view current openings and apply via the careers page on Oxford Biomedica’s official website.

Oxford Biomedica reported revenue of approximately £105 million in fiscal year 2023.

Yes, Oxford Biomedica participates in STEM education, charity events, and local community support programs.

Oxford Biomedica is GMP certified and holds ISO 9001 certification for quality management.

Oxford Biomedica’s main operations are in the UK, but it collaborates with partners globally and may have small satellite offices in the US and Europe.

Oxford Biomedica plans to expand capacity, advance its proprietary pipeline, and invest in next-generation vector technologies and sustainability.

The company follows strict GMP guidelines, employs rigorous analytical testing, and maintains a robust quality management system.

Oxford Biomedica occasionally hosts open days and tours for academic and partner groups; inquiries can be made through the official website.

To further explore the biotech industry and enhance your digital presence, consider leveraging resources such as Oxford Biomedica’s official website for cutting-edge gene therapy insights. Additionally, you can enhance your online visibility through Paid Guest Posting Sites, which offer Guest Post Backlinks, Guest Post Service Provider solutions, SEO Guest Posting Services, Guest Post Outreach Services, Order Guest Posting Service options, and Guest Post Packages Pricing. These services enable you to Buy Guest Post Packages and strengthen your website’s authority. When combined with the credibility of Oxford Biomedica’s innovations, a robust content marketing strategy can amplify reach in the healthcare and biotech sectors.